Can the HPV vaccine protect transplant patients? new study investigates
NCT ID NCT05557370
First seen May 02, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study looks at how well the HPV9 vaccine (Gardasil 9) works in people who have had a kidney transplant. About 30 adults aged 18 to 45 who are at least 6 months post-transplant will receive the vaccine. Researchers will measure their antibody levels over 2 years and compare them to published data from healthy individuals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.